Form 15-12G - Securities registration termination [Section 12(g)]
March 01 2024 - 3:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF
REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT
OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS
13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission
File Number: 001-36783
Bellicum Pharmaceuticals, Inc.
(Exact name of registrant
as specified in its charter)
3730 Kirby Drive, Suite 1200
Houston, TX 77098
(281) 454-3424
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
Common Stock, par value $0.01 per share
(Title of each class of securities covered by this
Form)
None
(Titles of all other classes of securities for which
a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
Rule 12g-4(a)(1) |
|
☒ |
Rule 12g-4(a)(2) |
|
☐ |
Rule 12h-3(b)(1)(i) |
|
☒ |
Rule 12h-3(b)(1)(ii) |
|
☐ |
Rule 15d-6 |
|
☐ |
Rule 15d-22(b) |
|
☐ |
Approximate number of holders of record as of the certification
or notice date: Less than 300
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, Bellicum Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned
duly authorized person.
|
|
|
|
|
|
|
|
|
|
|
BELLICUM PHARMACEUTICALS, INC. |
|
|
|
|
Date: March 1, 2024 |
|
|
|
By: |
|
/s/ Dave Maggio |
|
|
|
|
Name: |
|
Dave Maggio |
|
|
|
|
Title: |
|
Chief Executive Officer |
Bellicum Pharmaceuticals (PK) (USOTC:BLCM)
Historical Stock Chart
From Apr 2024 to May 2024
Bellicum Pharmaceuticals (PK) (USOTC:BLCM)
Historical Stock Chart
From May 2023 to May 2024